A clinical trial for early-stage breast cancer patients with BRCA gene mutations has reported 100% survival after three years. 

In a Phase III trial, Cancer Research UK researchers stopped BRCA-linked breast cancers growing or coming back by giving patients olaparib tablets 48 hours after each chemotherapy dose.  

All 39 of the patients who received the new combination survived at least three years after surgery. The three-year survival was 88% for people who just received the standard chemotherapy. 

The results, published in Nature Communications, suggest olaparib and chemotherapy could become the best treatment option for breast cancers caused by inherited BRCA mutations. 

Professor Jean Abraham, who led the trial at Addenbrooke’s Hospital in Cambridge, said: “It’s rare to have a 100% survival rate in a study like this, and for these aggressive types of cancer. We’re incredibly excited about the potential of this new approach, as it’s crucial that we find a way to treat and hopefully cure patients who are diagnosed with BRCA1 and BRCA2 related cancers”. 

Around one in 50 breast cancers are caused by BRCA gene mutations, which can run in families. Olaparib is designed to target specific weaknesses in cancers caused by BRCA mutations. For early-stage breast cancers, it’s currently used after surgery to target any remaining breast cancer cells. 

Professor Abraham and Mark O’Connor, Chief Scientist at AstraZeneca, designed the PARTNER trial to test whether spacing out chemotherapy and olaparib before surgery could make it possible to safely combine their strengths.  

Almost 10 years on, their results show that giving olaparib tablets 48 hours after each dose of chemotherapy leads to better outcomes for women with early-stage breast cancers caused by BRCA mutations.  

The team are now planning a larger, multinational trial with 600 patients to validate their results.

Diana Spencer, Senior Digital Content Editor, DDW